CN101676267A - N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐 - Google Patents
N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐 Download PDFInfo
- Publication number
- CN101676267A CN101676267A CN200810149651A CN200810149651A CN101676267A CN 101676267 A CN101676267 A CN 101676267A CN 200810149651 A CN200810149651 A CN 200810149651A CN 200810149651 A CN200810149651 A CN 200810149651A CN 101676267 A CN101676267 A CN 101676267A
- Authority
- CN
- China
- Prior art keywords
- compd
- mesylate
- compound
- salt
- pharmacologically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
大鼠1 | 大鼠2 | 大鼠3 | Mean±SD | |
Cmax(ng/ml) | 60.8 | 68.9 | 79.2 | 69.6±9.2 |
Tmax(h) | 1.5 | 1.5 | 1 | 1.33±0.29 |
AUC0-8h | 172 | 295 | 211 | 226±63 |
(ng·h/ml) | ||||
T1/2(h) | 2.13 | 1.12 | 2.09 | 1.78±0.57 |
Kel(h-1) | 0.325 | 0.622 | 0.332 | 0.426±0.169 |
MRT(h) | 3.20 | 3.38 | 3.32 | 3.30±0.09 |
CL(L/h/kg) | 115 | 67.4 | 92.7 | 91.5±23.6 |
Vd(L/kg) | 366 | 228 | 308 | 300±69.4 |
Claims (10)
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101496511A CN101676267B (zh) | 2008-09-16 | 2008-09-16 | N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐 |
PCT/CN2009/072239 WO2010031266A1 (zh) | 2008-09-16 | 2009-06-11 | N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐 |
MX2011002816A MX2011002816A (es) | 2008-09-16 | 2009-06-11 | Sales de n-[4-(1-cianociclopentil)fenil]-2-(4-piridimetil) amino-3-piridinacarboxamida. |
KR1020117008504A KR101674227B1 (ko) | 2008-09-16 | 2009-06-11 | N-[4-(1-사이아노사이클로펜틸)페닐]-2-(4-피리딜메틸)아미노-3-피리딘카복스아마이드의 염 |
EP09813987.6A EP2327697B1 (en) | 2008-09-16 | 2009-06-11 | The salts of n-(4-(1-cyanocyclopentyl)phenyl)-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide |
AU2009295168A AU2009295168B2 (en) | 2008-09-16 | 2009-06-11 | The salts of N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide |
BRPI0919018A BRPI0919018A2 (pt) | 2008-09-16 | 2009-06-11 | sal farmaceuticamente aceitável, uso de sal, e, processo para a preparação de sal |
CA2736664A CA2736664C (en) | 2008-09-16 | 2009-06-11 | The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide |
JP2011526364A JP5649132B2 (ja) | 2008-09-16 | 2009-06-11 | N−[4−(1−シアノシクロペンチル)フェニル]−2−(4−ピリジルメチル)アミノ−3−ピリジンカルボキサミドの塩 |
US13/063,850 US8362256B2 (en) | 2008-09-16 | 2009-06-11 | Salts of N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide |
RU2011113229/04A RU2499796C2 (ru) | 2008-09-16 | 2009-06-11 | Соли n-[4-(1-цианоциклопентил)фенил]-2-(4-пиридилметил)амино-3-пиридинкарбоксамида |
HK10107871.7A HK1141514A1 (zh) | 2008-09-16 | 2010-08-18 | |
ZA2011/01891A ZA201101891B (en) | 2008-09-16 | 2011-03-11 | The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101496511A CN101676267B (zh) | 2008-09-16 | 2008-09-16 | N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101676267A true CN101676267A (zh) | 2010-03-24 |
CN101676267B CN101676267B (zh) | 2012-12-26 |
Family
ID=42029001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101496511A Active CN101676267B (zh) | 2008-09-16 | 2008-09-16 | N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐 |
Country Status (13)
Country | Link |
---|---|
US (1) | US8362256B2 (zh) |
EP (1) | EP2327697B1 (zh) |
JP (1) | JP5649132B2 (zh) |
KR (1) | KR101674227B1 (zh) |
CN (1) | CN101676267B (zh) |
AU (1) | AU2009295168B2 (zh) |
BR (1) | BRPI0919018A2 (zh) |
CA (1) | CA2736664C (zh) |
HK (1) | HK1141514A1 (zh) |
MX (1) | MX2011002816A (zh) |
RU (1) | RU2499796C2 (zh) |
WO (1) | WO2010031266A1 (zh) |
ZA (1) | ZA201101891B (zh) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104072412A (zh) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐b晶型及其制备方法和应用 |
CN104072413A (zh) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐a晶型及其制备方法和应用 |
CN104072410A (zh) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐d晶型及其制备方法和应用 |
CN104072411A (zh) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐c晶型及其制备方法和应用 |
CN104086483A (zh) * | 2014-07-08 | 2014-10-08 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐f晶型及其制备方法和应用 |
CN104086484A (zh) * | 2014-07-08 | 2014-10-08 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐溶剂化物晶体及其制备方法和应用 |
CN105541708A (zh) * | 2014-10-28 | 2016-05-04 | 华东理工常熟研究院有限公司 | 硫酸阿帕替尼的新晶型 |
CN105622498A (zh) * | 2014-10-28 | 2016-06-01 | 华东理工常熟研究院有限公司 | 硫酸阿帕替尼的新晶型 |
CN105622499A (zh) * | 2014-10-28 | 2016-06-01 | 华东理工常熟研究院有限公司 | 硫酸阿帕替尼的新晶型 |
CN105801476A (zh) * | 2016-04-13 | 2016-07-27 | 上海宣创生物科技有限公司 | 阿帕替尼甲磺酸盐ii晶型及其制备方法和应用 |
CN106243031A (zh) * | 2016-07-26 | 2016-12-21 | 江苏恒瑞医药股份有限公司 | 一种阿帕替尼的制备方法 |
CN106963948A (zh) * | 2017-05-12 | 2017-07-21 | 顾艳宏 | 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用 |
WO2018068691A1 (zh) | 2016-10-10 | 2018-04-19 | 苏州盛迪亚生物医药有限公司 | 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途 |
CN108250138A (zh) * | 2016-12-28 | 2018-07-06 | 上海宣创生物科技有限公司 | 阿帕替尼a晶型及其制备方法和应用 |
WO2019034048A1 (zh) * | 2017-08-15 | 2019-02-21 | 江苏恒瑞医药股份有限公司 | 一种vegfr抑制剂晶型及其制备方法 |
CN109394685A (zh) * | 2017-08-15 | 2019-03-01 | 江苏恒瑞医药股份有限公司 | 一种vegfr抑制剂的药物组合物及其制备方法 |
CN109942487A (zh) * | 2017-12-21 | 2019-06-28 | 江苏恒瑞医药股份有限公司 | 一种吡啶类化合物及其制备方法、用途 |
WO2019129168A1 (zh) | 2017-12-29 | 2019-07-04 | 江苏恒瑞医药股份有限公司 | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 |
WO2021203769A1 (zh) * | 2020-04-10 | 2021-10-14 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6714017B6 (ja) | 2015-04-15 | 2020-07-22 | ダウ グローバル テクノロジーズ エルエルシー | 垂直方向に伸長された気泡を有する断熱発泡体 |
CN108778336A (zh) | 2016-12-01 | 2018-11-09 | 江苏恒瑞医药股份有限公司 | 一种vegfr抑制剂与parp抑制剂联合在制备治疗胃癌的药物中的用途 |
CN109381436A (zh) * | 2017-08-14 | 2019-02-26 | 江苏恒瑞医药股份有限公司 | 阿帕替尼药物组合物及其制备方法 |
WO2019094832A1 (en) * | 2017-11-10 | 2019-05-16 | Lsk Biopharma | A combination therapy with apatinib for the treatment of cancer |
TW201924720A (zh) | 2017-12-06 | 2019-07-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Parp抑制劑用於治療化療耐藥的卵巢癌或乳腺癌的用途 |
WO2020051173A1 (en) | 2018-09-05 | 2020-03-12 | Assia Chemical Industries Ltd | New crystalline polymorphs of rivoceranib and rivoceranib mesylate |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040259916A1 (en) * | 2003-06-16 | 2004-12-23 | Chen Guoqing P. | Six membered amino-amide derivatives an angiogenisis inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
MXPA04012948A (es) * | 2002-07-31 | 2005-09-12 | Schering Ag | Inhibidores antranilamidopiridinas vegfr-2 y vegfr-3. |
CN1281590C (zh) * | 2002-11-27 | 2006-10-25 | 南京凯衡科贸有限公司 | 具有抑制血管生成活性的六员氨基酰胺类衍生物 |
TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
-
2008
- 2008-09-16 CN CN2008101496511A patent/CN101676267B/zh active Active
-
2009
- 2009-06-11 BR BRPI0919018A patent/BRPI0919018A2/pt not_active Application Discontinuation
- 2009-06-11 US US13/063,850 patent/US8362256B2/en active Active
- 2009-06-11 KR KR1020117008504A patent/KR101674227B1/ko active IP Right Grant
- 2009-06-11 RU RU2011113229/04A patent/RU2499796C2/ru active
- 2009-06-11 EP EP09813987.6A patent/EP2327697B1/en active Active
- 2009-06-11 MX MX2011002816A patent/MX2011002816A/es active IP Right Grant
- 2009-06-11 WO PCT/CN2009/072239 patent/WO2010031266A1/zh active Application Filing
- 2009-06-11 CA CA2736664A patent/CA2736664C/en active Active
- 2009-06-11 AU AU2009295168A patent/AU2009295168B2/en active Active
- 2009-06-11 JP JP2011526364A patent/JP5649132B2/ja active Active
-
2010
- 2010-08-18 HK HK10107871.7A patent/HK1141514A1/xx unknown
-
2011
- 2011-03-11 ZA ZA2011/01891A patent/ZA201101891B/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040259916A1 (en) * | 2003-06-16 | 2004-12-23 | Chen Guoqing P. | Six membered amino-amide derivatives an angiogenisis inhibitors |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016004873A1 (zh) * | 2014-07-08 | 2016-01-14 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐a晶型及其制备方法和应用 |
CN104072410A (zh) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐d晶型及其制备方法和应用 |
CN104961676B (zh) * | 2014-07-08 | 2016-04-27 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐a晶型及其制备方法和应用 |
CN105017142B (zh) * | 2014-07-08 | 2017-02-22 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐b晶型及其制备方法和应用 |
CN104086483A (zh) * | 2014-07-08 | 2014-10-08 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐f晶型及其制备方法和应用 |
CN104086484A (zh) * | 2014-07-08 | 2014-10-08 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐溶剂化物晶体及其制备方法和应用 |
CN104961676A (zh) * | 2014-07-08 | 2015-10-07 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐a晶型及其制备方法和应用 |
CN105017142A (zh) * | 2014-07-08 | 2015-11-04 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐b晶型及其制备方法和应用 |
CN104072410B (zh) * | 2014-07-08 | 2017-02-08 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐d晶型及其制备方法和应用 |
CN104072413A (zh) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐a晶型及其制备方法和应用 |
CN104072411A (zh) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐c晶型及其制备方法和应用 |
CN104086484B (zh) * | 2014-07-08 | 2016-05-25 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐溶剂化物晶体及其制备方法和应用 |
CN104072412A (zh) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐b晶型及其制备方法和应用 |
CN105712929A (zh) * | 2014-07-08 | 2016-06-29 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物甲磺酸盐a晶型及其制备方法和应用 |
CN105622499A (zh) * | 2014-10-28 | 2016-06-01 | 华东理工常熟研究院有限公司 | 硫酸阿帕替尼的新晶型 |
CN105622498A (zh) * | 2014-10-28 | 2016-06-01 | 华东理工常熟研究院有限公司 | 硫酸阿帕替尼的新晶型 |
CN105541708A (zh) * | 2014-10-28 | 2016-05-04 | 华东理工常熟研究院有限公司 | 硫酸阿帕替尼的新晶型 |
CN105801476A (zh) * | 2016-04-13 | 2016-07-27 | 上海宣创生物科技有限公司 | 阿帕替尼甲磺酸盐ii晶型及其制备方法和应用 |
CN106243031A (zh) * | 2016-07-26 | 2016-12-21 | 江苏恒瑞医药股份有限公司 | 一种阿帕替尼的制备方法 |
CN106243031B (zh) * | 2016-07-26 | 2017-09-08 | 江苏恒瑞医药股份有限公司 | 一种阿帕替尼的制备方法 |
CN108601831B (zh) * | 2016-10-10 | 2019-11-12 | 苏州盛迪亚生物医药有限公司 | 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途 |
WO2018068691A1 (zh) | 2016-10-10 | 2018-04-19 | 苏州盛迪亚生物医药有限公司 | 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途 |
US11866500B2 (en) | 2016-10-10 | 2024-01-09 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers |
CN108601831A (zh) * | 2016-10-10 | 2018-09-28 | 苏州盛迪亚生物医药有限公司 | 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途 |
US11208484B2 (en) | 2016-10-10 | 2021-12-28 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers |
CN108250138A (zh) * | 2016-12-28 | 2018-07-06 | 上海宣创生物科技有限公司 | 阿帕替尼a晶型及其制备方法和应用 |
CN106963948A (zh) * | 2017-05-12 | 2017-07-21 | 顾艳宏 | 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用 |
CN109394685A (zh) * | 2017-08-15 | 2019-03-01 | 江苏恒瑞医药股份有限公司 | 一种vegfr抑制剂的药物组合物及其制备方法 |
CN110637010A (zh) * | 2017-08-15 | 2019-12-31 | 江苏恒瑞医药股份有限公司 | 一种vegfr抑制剂晶型及其制备方法 |
CN109394685B (zh) * | 2017-08-15 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 一种vegfr抑制剂的药物组合物及其制备方法 |
WO2019034048A1 (zh) * | 2017-08-15 | 2019-02-21 | 江苏恒瑞医药股份有限公司 | 一种vegfr抑制剂晶型及其制备方法 |
CN109942487A (zh) * | 2017-12-21 | 2019-06-28 | 江苏恒瑞医药股份有限公司 | 一种吡啶类化合物及其制备方法、用途 |
WO2019129168A1 (zh) | 2017-12-29 | 2019-07-04 | 江苏恒瑞医药股份有限公司 | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 |
WO2021203769A1 (zh) * | 2020-04-10 | 2021-10-14 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2010031266A1 (zh) | 2010-03-25 |
KR101674227B1 (ko) | 2016-11-08 |
MX2011002816A (es) | 2011-04-05 |
AU2009295168A1 (en) | 2010-03-25 |
JP2012502885A (ja) | 2012-02-02 |
BRPI0919018A2 (pt) | 2015-12-08 |
EP2327697A4 (en) | 2012-06-06 |
JP5649132B2 (ja) | 2015-01-07 |
HK1141514A1 (zh) | 2010-11-12 |
CN101676267B (zh) | 2012-12-26 |
US8362256B2 (en) | 2013-01-29 |
KR20110059877A (ko) | 2011-06-07 |
ZA201101891B (en) | 2012-05-30 |
CA2736664A1 (en) | 2010-03-25 |
CA2736664C (en) | 2016-05-24 |
US20110184023A1 (en) | 2011-07-28 |
RU2011113229A (ru) | 2012-10-27 |
AU2009295168B2 (en) | 2014-02-13 |
EP2327697B1 (en) | 2014-03-12 |
EP2327697A1 (en) | 2011-06-01 |
RU2499796C2 (ru) | 2013-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101676267B (zh) | N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐 | |
US10851061B2 (en) | Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use | |
JP7319383B2 (ja) | マルチターゲットキナーゼ阻害剤、医薬組成物、並びにマルチターゲットキナーゼ阻害剤の製造方法及び適用 | |
CN105153026B (zh) | 含联芳基酰胺结构的索拉非尼衍生物及其制备方法和应用 | |
CN103561734B (zh) | 用于治疗头颈部鳞状细胞癌的协同的药物组合 | |
CN102786469B (zh) | 邻吡啶酰肼衍生物及其制法和药物组合物与用途 | |
CN107573340A (zh) | 2‑氨甲酰基‑4‑芳杂吡啶类化合物的制备及应用 | |
CN109988151A (zh) | 一种炔类化合物、制备方法及其应用 | |
CN104557870A (zh) | 一种吡啶胺化合物的富马酸盐 | |
TW200536529A (en) | Dosage forms and methods of treatment using VEGFR inhibitors | |
CN113274390B (zh) | 哌马色林在制备抗肿瘤药物中的应用 | |
CN109265444A (zh) | 取代的三嗪类idh抑制剂的光学异构体及其应用 | |
CN107513040A (zh) | 取代苯并嘧啶类化合物的制备及分子靶向肿瘤治疗药物的应用 | |
TWI462738B (zh) | N-〔4-(1-氰基環戊基)苯基〕-2-(4-吡啶甲基)胺基-3-吡啶甲醯胺的鹽 | |
TW202039423A (zh) | 戊烷脒之類似物及其用途 | |
CN114957137B (zh) | N-(1,2,3,6-四氢嘧啶-4-基)-2-苯基乙酰胺类化合物及其制备与应用 | |
CN103570616B (zh) | N′‑直链烷酰基邻吡啶酰肼衍生物及其制法和药物组合物与用途 | |
CN118047725A (zh) | Vegfr抑制剂及其制备方法和应用 | |
CN106279101A (zh) | 苯并吡唑联吡啶类化合物、包含此类化合物的药物组合物及其用途 | |
Larocque et al. | Nicotinamide-ponatinib, HSN748, a potent anti-CML and anti-AML compound with better kinase selectivity than ponatinib | |
WO2023239945A1 (en) | Btological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5- yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan- 7-ol crystalline, phosphoric acid salt and its enantiomers | |
NZ723714B2 (en) | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1141514 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1141514 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: HENGRUI PHARMACEUTICAL CO., LTD., SHANGHAI Effective date: 20130717 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 222002 LIANYUNGANG, JIANGSU PROVINCE TO: 222047 LIANYUNGANG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130717 Address after: 222047 Kunlun Road, Lianyungang economic and Technological Development Zone, Jiangsu, No. 7 Patentee after: Hengrui Medicine Co., Ltd., Jiangsu Prov. Patentee after: Hengrui Pharmaceutical Co., Ltd., Shanghai Address before: 222002 No. 145, Renmin East Road, Sinpo District, Jiangsu, Lianyungang Patentee before: Hengrui Medicine Co., Ltd., Jiangsu Prov. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160914 Address after: 222047 Kunlun Road, Lianyungang economic and Technological Development Zone, Jiangsu, No. 7 Patentee after: Hengrui Medicine Co., Ltd., Jiangsu Prov. Patentee after: Hengrui Pharmaceutical Co., Ltd., Shanghai Patentee after: Jiangsu Sheng Di Pharmaceutical Co., Ltd. Address before: 222047 Kunlun Road, Lianyungang economic and Technological Development Zone, Jiangsu, No. 7 Patentee before: Hengrui Medicine Co., Ltd., Jiangsu Prov. Patentee before: Hengrui Pharmaceutical Co., Ltd., Shanghai |